Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Ocana

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Plos One|March 28, 2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyAmirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, et al.
Geroscience|February 15, 2026
Subtype-specific sirtuin expression signatures link mitochondrial-epigenetic networks to breast cancer survivalZoltan Ungvari, Otília Menyhárt, Alberto Ocana, et al.
JAMA Oncology|December 7, 2018
Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient AccrualDaniel Shepshelovich, Ariadna Tibau, Consolación Molto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysisSaroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.
JAMA Oncology|March 5, 2016
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug AdministrationAriadna Tibau, Alberto Ocana, Geòrgia Anguera, et al.
Cancer Treatment Reviews|September 8, 2017
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysisHadar Goldvaser, Ibrahim AlGorashi, Domen Ribnikar, et al.
Biomarker Research|March 15, 2025
Integrating artificial intelligence in drug discovery and early drug development: a transformative approachAlberto Ocana, Atanasio Pandiella, Cristian Privat, et al.
Cancer Treatment Reviews|June 15, 2013
Fulvestrant for advanced breast cancer: a meta-analysisMustafa Al-Mubarak, Adrian G Sacher, Alberto Ocana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugsSaroj Niraula, Bostjan Seruga, Alberto Ocana, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Plos One|March 28, 2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyAmirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, et al.
Geroscience|February 15, 2026
Subtype-specific sirtuin expression signatures link mitochondrial-epigenetic networks to breast cancer survivalZoltan Ungvari, Otília Menyhárt, Alberto Ocana, et al.
JAMA Oncology|December 7, 2018
Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient AccrualDaniel Shepshelovich, Ariadna Tibau, Consolación Molto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysisSaroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.
JAMA Oncology|March 5, 2016
Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug AdministrationAriadna Tibau, Alberto Ocana, Geòrgia Anguera, et al.
Cancer Treatment Reviews|September 8, 2017
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysisHadar Goldvaser, Ibrahim AlGorashi, Domen Ribnikar, et al.
Biomarker Research|March 15, 2025
Integrating artificial intelligence in drug discovery and early drug development: a transformative approachAlberto Ocana, Atanasio Pandiella, Cristian Privat, et al.
Cancer Treatment Reviews|June 15, 2013
Fulvestrant for advanced breast cancer: a meta-analysisMustafa Al-Mubarak, Adrian G Sacher, Alberto Ocana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugsSaroj Niraula, Bostjan Seruga, Alberto Ocana, et al.
Pageof 10